GSK (LON:GSK) Given “Underweight” Rating at JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating restated by equities research analysts at JPMorgan Chase & Co. in a report released on Wednesday,Digital Look reports.

GSK has been the topic of a number of other research reports. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a report on Wednesday. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Thursday. Finally, Berenberg Bank boosted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of GBX 1,762.

GSK Stock Up 0.1%

Shares of GSK stock traded up GBX 1.25 during midday trading on Wednesday, reaching GBX 1,902.75. 7,630,360 shares of the stock were exchanged, compared to its average volume of 6,804,678. GSK has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 1,909.73. The firm has a market cap of £76.76 billion, a PE ratio of 14.31, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company’s 50 day moving average is GBX 1,805.21 and its two-hundred day moving average is GBX 1,595.16. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds purchased 1,650 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker bought 441 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was acquired at an average cost of GBX 1,809 per share, with a total value of £7,977.69. 0.20% of the stock is owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.